In summary, considering that many efficient protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole and tetrabromo-benzotriazole exhibit low cytotoxicity, in this study, we aimed at designing of acyl-prodrugs of well-established CK2 inhibitors as a novel therapeutic strategy against breast cancer. This evidence concerns the gene WEE1 and breast carcinoma.